129 related articles for article (PubMed ID: 38729306)
1. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
Pandey K; Acharya A; Pal D; Jain P; Singh K; Durden DL; Kutateladze TG; Deshpande AJ; Byrareddy SN
Antiviral Res; 2024 Jul; 227():105904. PubMed ID: 38729306
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
3. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.
Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D
Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683
[TBL] [Abstract][Full Text] [Related]
8. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
[TBL] [Abstract][Full Text] [Related]
9. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF
Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598
[TBL] [Abstract][Full Text] [Related]
10. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
[TBL] [Abstract][Full Text] [Related]
11. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.
Bakovic A; Risner K; Bhalla N; Alem F; Chang TL; Weston WK; Harness JA; Narayanan A
Viruses; 2021 Feb; 13(2):. PubMed ID: 33572467
[TBL] [Abstract][Full Text] [Related]
12. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval.
Ashour NA; Abo Elmaaty A; Sarhan AA; Elkaeed EB; Moussa AM; Erfan IA; Al-Karmalawy AA
Drug Des Devel Ther; 2022; 16():685-715. PubMed ID: 35321497
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
[TBL] [Abstract][Full Text] [Related]
15. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.
Nair MS; Huang Y; Fidock DA; Polyak SJ; Wagoner J; Towler MJ; Weathers PJ
J Ethnopharmacol; 2021 Jun; 274():114016. PubMed ID: 33716085
[TBL] [Abstract][Full Text] [Related]
16. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
[TBL] [Abstract][Full Text] [Related]
18. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
19. The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
Martinez DR; Moreira FR; Catanzaro NJ; Diefenbacher MV; Zweigart MR; Gully KL; De la Cruz G; Brown AJ; Adams LE; Yount B; Baric TJ; Mallory ML; Conrad H; May SR; Dong S; Scobey DT; Nguyen C; Montgomery SA; Perry JK; Babusis D; Barrett KT; Nguyen AH; Nguyen AQ; Kalla R; Bannister R; Feng JY; Cihlar T; Baric RS; Mackman RL; Bilello JP; Schäfer A; Sheahan TP
Sci Transl Med; 2024 May; 16(748):eadj4504. PubMed ID: 38776389
[TBL] [Abstract][Full Text] [Related]
20. Small-Molecule Antiviral β-d-
Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]